HomeCompareVKSC vs JNJ

VKSC vs JNJ: Dividend Comparison 2026

VKSC yields 19.65% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VKSC wins by $41.2K in total portfolio value
10 years
VKSC
VKSC
● Live price
19.65%
Share price
$10.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.5K
Annual income
$6,488.77
Full VKSC calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — VKSC vs JNJ

📍 VKSC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVKSCJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VKSC + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VKSC pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VKSC
Annual income on $10K today (after 15% tax)
$1,670.01/yr
After 10yr DRIP, annual income (after tax)
$5,515.45/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, VKSC beats the other by $1,529.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VKSC + JNJ for your $10,000?

VKSC: 50%JNJ: 50%
100% JNJ50/50100% VKSC
Portfolio after 10yr
$50.9K
Annual income
$5,589.09/yr
Blended yield
10.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VKSC
No analyst data
Altman Z
1.0
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VKSC buys
0
JNJ buys
0
No recent congressional trades found for VKSC or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVKSCJNJ
Forward yield19.65%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$71.5K$30.3K
Annual income after 10y$6,488.77$4,689.40
Total dividends collected$40.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VKSC vs JNJ ($10,000, DRIP)

YearVKSC PortfolioVKSC Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,665$1,964.72$10,592$272.30+$2.1KVKSC
2$15,877$2,325.48$11,289$357.73+$4.6KVKSC
3$19,713$2,724.55$12,123$472.89+$7.6KVKSC
4$24,254$3,161.51$13,141$629.86+$11.1KVKSC
5$29,587$3,635.38$14,408$846.81+$15.2KVKSC
6$35,803$4,144.63$16,021$1,151.60+$19.8KVKSC
7$42,996$4,687.23$18,122$1,588.22+$24.9KVKSC
8$51,267$5,260.73$20,930$2,228.20+$30.3KVKSC
9$60,718$5,862.28$24,792$3,191.91+$35.9KVKSC
10$71,457$6,488.77$30,274$4,689.40+$41.2KVKSC

VKSC vs JNJ: Complete Analysis 2026

VKSCStock

Viskase Companies, Inc., together with its subsidiaries, produces and sells nonedible cellulosic, fibrous, and plastic casings for preparing and packaging processed meat products in North America, South America, Europe, Asia, and internationally. The company offers NOJAX cellulose casings for use in the automated production of hot dogs, dry mini salamis, and cooked and coarse ground sausages; and large cellulose casings for giving cylindrical or oval shape to the processed meats that are used in bologna, mortadella, deli ham, bierwurst, and dry sausages. It also provides fibrous casings for use in a range of applications, including pepperoni, salami, luncheon meats, boneless hams, and other deli-style processed meats, as well as for processed and smoked cheeses; color transfer casings for a range of natural and synthetic shades; flavor transfer casings for taste profiles; smoke transfer casings for processed meat or cheese products; and spice transfer casings for processing facility. In addition, the company offers VISDRY casings for dried or smoked sausages; VISFLEX casings for cheese and processed meat; VISFLEX casings for a range of cheese and processed meat applications; VISMAX casings for molded, and formed processed meat and poultry applications; VISLON for meat, poultry, and cheese applications; VISMOKE casings for cooked and smoked meat products, semi-dry sausages, and spreadable dry sausages; VISCOAT casings for a range of applications, including turkey, ham, and roast beef products; and POLYJAX casings for the production of hot dog, sausage, chorizo products, and meat snack sticks. Further, it offers textile spice transfer casings for transfer of the spice to the food and MEMBRA-CEL, a dialysis membrane made from regenerated cellulose. The company was founded in 1925 and is based in Lombard, Illinois. Viskase Companies, Inc. is a subsidiary of Icahn Enterprises L.P.

Full VKSC Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VKSC vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VKSC vs SCHDVKSC vs JEPIVKSC vs OVKSC vs KOVKSC vs MAINVKSC vs ABBVVKSC vs MRKVKSC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.